BioPharmSignal logoBioPharmSignal

Biotech News

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Ensysce Biosciences (ENSC)Ensysce BiosciencesCompany update

ENSC (ENSC) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is ensc.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

ENSCEnsysce Biosciences2026-06-26 12:00 EST

Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study

ENSCEnsysce Biosciences2026-04-16 12:00 EST

Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study

View all latest news

Ensysce Biosciences

Ensysce Biosciences is a biotechnology company focused on abuse-deterrent and safer opioid-related technologies. Its story is built around opioid safety, pain management, and formulation science.

Recent company news

ENSCEnsysce Biosciences2026-08-06 12:00 EST

Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing

ENSCEnsysce Biosciences2026-07-14 12:00 EST

Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant

ENSCEnsysce Biosciences2026-06-26 12:00 EST

Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study

ENSCEnsysce Biosciences2026-05-15 20:15 EST

Ensysce Biosciences Reports First Quarter 2026 Financial Results

ENSCEnsysce Biosciences2026-05-12 12:00 EST

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Stock data

Close
0.52 USD
Market cap
3.84M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States